Page 48 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 1 The Etiology of Cancer 27

37. Modiano JF, Johnson LD, Bellgrau D: Negative regulators in 60. Fidler IJ: The pathogenesis of cancer metastasis: the ‘seed and soil’
homeostasis of naive peripheral T cells, Immunol Res 41:137–153, hypothesis revisited, Nat Rev Cancer 3:453–458, 2003.
2008. 61. Kim JW, Wong CW, Goldsmith JD, et al.: Rapid apoptosis in the
VetBooks.ir 38. Scott MC, Temiz NA, Sarver AE, et al.: Comparative transcrip- pulmonary vasculature distinguishes non-metastatic from meta-
static melanoma cells, Cancer Lett 213:203–212, 2004.
tome analysis quantifies immune cell transcript levels, metastatic
progression, and survival in osteosarcoma, Cancer Res 78:326–337,
breast cancer cells after spontaneous metastasis to the lung, Am J
2018. 62. Wong CW, Song C, Grimes MM, et al.: Intravascular location of
39. Fosmire SP, Thomas R, Jubala CM, et al.: Inactivation of the p16 Pathol 161:749–753, 2002.
cyclin-dependent kinase inhibitor in high-grade canine non-Hodg- 63. Wong CW, Lee A, Shientag L, et al.: Apoptosis: an early event in
kin’s T-cell lymphoma, Vet Pathol 44:467–478, 2007. metastatic inefficiency, Cancer Res 61:333–338, 2001.
40. Modiano JF, Breen M, Valli VE, et al.: Predictive value of p16 64. Koshkina NV, Khanna C, Mendoza A, et al.: Fas-negative osteo-
or Rb inactivation in a model of naturally occurring canine non- sarcoma tumor cells are selected during metastasis to the lungs: the
Hodgkin’s lymphoma, Leukemia 21:184–187, 2007. role of the Fas pathway in the metastatic process of osteosarcoma,
41. Sarver AL, Mills L, T’emiz N, et al.: Comparative genomic analyses Mol Cancer Res 5:991–999, 2007.
of osteosarcoma etiology reveal a chromosomal structural rationale 65. Krishnan K, Bruce B, Hewitt S, et al.: Ezrin mediates growth and
for the increased incidence of osteosarcoma in dogs, Annual Meeting survival in Ewing’s sarcoma through the AKT/mTOR, but not the
of the American Association for Cancer Research, 2018; Asbtract #3399. MAPK, signaling pathway, Clin Exp Metastasis 23:227–236, 2006.
42. Kim JH, Megquier K, Sarver AL, et al.: Mutational and transcrip- 66. Hunter KW, Amin R, Deasy S, et al.: Genetic insights into the
tomic profiling identify distinct angiogenic and inflammatory sub- morass of metastatic heterogeneity, Nat Rev Cancer 18:211–223,
types of angiosarcoma, Annual Meeting of the American Association 2018.
for Cancer Research, 2018; Asbtract #5357. 67. Scala S: Molecular pathways: targeting the CXCR4-CXCL12
43. Hammerman PS, Fox CJ, Thompson CB: Beginnings of a signal- axis—untapped potential in the tumor microenvironment, Clin
transduction pathway for bioenergetic control of cell survival, Cancer Res 21:4278–4285, 2015.
Trends Biochem Sci 29:586–592, 2004. 68. Im KS, Graef AJ, Breen M, et al.: Interactions between CXCR4
44. White E, DiPaola RS: The double-edged sword of autophagy mod- and CXCL12 promote cell migration and invasion of canine hem-
ulation in cancer, Clin Cancer Res 15:5308–5316, 2009. angiosarcoma, Vet Comp Oncol 15:315–327, 2017.
45. Ohyashiki JH, Sashida G, Tauchi T, et al.: Telomeres and telomer- 69. Byrum ML, Pondenis HC, Fredrickson RL, et al.: Downregulation
ase in hematologic neoplasia, Oncogene 21:680–687, 2002. of CXCR4 expression and functionality after zoledronate exposure
46. Pang LY, Argyle DJ: Using naturally occurring tumours in dogs in canine osteosarcoma, J Vet Intern Med 30:1187–1196, 2016.
and cats to study telomerase and cancer stem cell biology, Biochim 70. Fan TM, Barger AM, Fredrickson RL, et al.: Investigating CXCR4
Biophys Acta 1792:380–391, 2009. expression in canine appendicular osteosarcoma, J Vet Intern Med
47. Folkman J: The role of angiogenesis in tumor growth, Semin Cancer 22:602–608, 2008.
Biol 3:65–71, 1992. 71. Boveri T: Concerning the origin of malignant tumours by The-
48. Folkman J: Tumor angiogenesis: therapeutic implications, N Engl J odor Boveri. Translated and annotated by Henry Harris, J Cell Sci
Med 285:1182–1186, 1971. 121(Suppl 1):1–84, 2008.
49. Ferrara N, Kerbel RS: Angiogenesis as a therapeutic target, Nature 72. Loeb LA: Mutator phenotype may be required for multistage carci-
438:967–974, 2005. nogenesis, Cancer Res 51:3075–3079, 1991.
50. Buysschaert I, Schmidt T, Roncal C, et al.: Genetics, epigenetics 73. Pihan G, Doxsey SJ: Mutations and aneuploidy: co-conspirators in
and pharmaco-(epi)genomics in angiogenesis, J Cell Mol Med cancer? Cancer Cell 4:89–94, 2003.
12:2533–2551, 2008. 74. Sjoblom T, Jones S, Wood LD, et al.: The consensus coding
51. Jain RK, Duda DG, Willett CG, et al.: Biomarkers of response and sequences of human breast and colorectal cancers, Science 314:268–
resistance to antiangiogenic therapy, Nat Rev Clin Oncol 6:327– 274, 2006.
338, 2009. 75. Breivik J: The evolutionary origin of genetic instability in cancer
52. Carmeliet P, Jain RK: Molecular mechanisms and clinical applica- development, Semin Cancer Biol 15:51–60, 2005.
tions of angiogenesis, Nature 473:298–307, 2011. 76. Albertson DG, Collins C, McCormick F, et al.: Chromosome aber-
53. Kim JH, Graef AJ, Dickerson EB, et al.: Pathobiology of heman- rations in solid tumors, Nat Genet 34:369–376, 2003.
giosarcoma in dogs: research advances and future perspectives, Vet 77. Teixeira MR, Heim S: Multiple numerical chromosome aberrations
Sci 2:388–405, 2015. in cancer: what are their causes and what are their consequences?
54. Tamburini BA, Phang TL, Fosmire SP, et al.: Gene expression pro- Semin Cancer Biol 15:3–12, 2005.
filing identifies inflammation and angiogenesis as distinguishing 78. Gollin SM: Mechanisms leading to chromosomal instability, Semin
features of canine hemangiosarcoma, BMC Cancer 10:619, 2010. Cancer Biol 15:33–42, 2005.
55. Tamburini BA, Trapp S, Phang TL, et al.: Gene expression profiles 79. Rajagopalan H, Lengauer C: Aneuploidy and cancer, Nature
of sporadic canine hemangiosarcoma are uniquely associated with 432:338–341, 2004.
breed, PLoS One 4:e5549, 2009. 80. Maser RS, DePinho RA: Connecting chromosomes, crisis, and
56. Clifford CA, Hughes D, Beal MW, et al.: Plasma vascular endo- cancer, Science 297:565–569, 2002.
thelial growth factor concentrations in healthy dogs and dogs with 81. Dvorak HF: Tumors: wounds that do not heal. Similarities between
hemangiosarcoma, J Vet Intern Med 15:131–135, 2001. tumor stroma generation and wound healing, N Engl J Med
57. Kim JH, Frantz AM, Anderson KL, et al.: Interleukin-8 promotes 315:1650–1659, 1986.
canine hemangiosarcoma growth by regulating the tumor microen- 82. Lin WW, Karin M: A cytokine-mediated link between innate
vironment, Exp Cell Res 323:155–164, 2014. immunity, inflammation, and cancer, J Clin Invest 117:1175–1183,
58. Rodriguez AM, Graef AJ, LeVine DN, et al.: Association of sphin- 2007.
gosine-1-phosphate (S1P)/S1P receptor-1 pathway with cell prolif- 83. Mantovani A, Allavena P, Sica A, et al.: Cancer-related inflamma-
eration and survival in canine hemangiosarcoma, J Vet Intern Med tion, Nature 454:436–444, 2008.
29:1088–1097, 2015. 84. Bhatia R, McGlave PB, Dewald GW, et al.: Abnormal function
59. Megquier K, Tonomura N, Fall T, et al.: Connecting inherited of the bone marrow microenvironment in chronic myelogenous
risk factors, tumor mutation profiles and clinical outcomes in golden leukemia: role of malignant stromal macrophages, Blood 85:3636–
retriever hemangiosarcoma, St. Paul, MN, 2017, International Con- 3645, 1995.
ference on Advances in Canine and Feline Genomics and Inherited 85. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation,
Diseases. and cancer, Cell 140:883–899, 2010.